Abstract
Background
Cutaneous Leishmaniasis (CL) is the most common form of leishmaniasis. CL can be divided into two major groups: acute CL (ACL) and chronic CL (CCL). The aim of this study is to compare the efficacy of miltefosin and pentavalent antimony compounds in vivo with the CCL patient samples.
Materials
Three study groups were formed, each consisting of five male Mus musculus (Balb/C) mice. In this model, promastigotes from the culture of a CCL patient were utilized. 100 μL L. tropica promastigote suspension with a density of 108 promastigotes/ml were injected into the hint-right footpad of each experimental animal intradermally. Footpads of the mice were measured every two weeks until 24th week. From the 13th week, miltefosin 50 mg/kg/day was administered orally using gavage for 21 days, Meglumin antimoniate (MA) was administered by intramuscular (IM) injection daily for 21 days at 50 mg/kg/day and saline was administered IM for 21 days for the miltefosine, MA and control group, respectively.
Results
The footpad measurements of the miltefosine group were lower than the control group statistically. Between the MA group and the miltefosine group and MA group and the control group, there was no statistically significant difference. Giemsa stained slides revealed amastigotes in one, two and all of the slides for the miltefosine, MA and control group, respectively. Molecular tests were performed with the Rotor-Gene device and L. tropica consistent peaks were obtained in one of the miltefosine group, four in the MA group and all mice in the control group.
Conclusions
Demonstration of both clinical and laboratory improvement in four of the five experimental animals provides strong evidence that miltefosine is an effective drug in the treatment of CCL. In the literature, no clinical or laboratory studies using miltefosine have been performed with CCL patients only.
Similar content being viewed by others
References
Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M (2016) Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 16:584–591. https://doi.org/10.1016/S1473-3099(16)00003-7
Du R, Hotez PJ, Al-Salem WS, Acosta-Serrano A (2016) Old world cutaneous leishmaniasis and refugee crises in the Middle East and North Africa. PLoSNegl Trop Dis 10:e0004545. https://doi.org/10.1371/journal.pntd.0004545
Abuzaid AA, Abdoon AM, Aldahan MA, Alzahrani AG, Alhakeem RF, Asiri AM et al (2017) Cutaneous leishmaniasis in Saudi Arabia: a comprehensive overview. Vector Borne Zoonotic Dis 17:673–684. https://doi.org/10.1089/vbz.2017.2119
Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581–596. https://doi.org/10.1016/S1473-3099(07)70209-8
Hotez PJ, Velasquez RM, Wolf JE (2014) Neglected tropical skin diseases: their global elimination through integrated mass drug administration? JAMA Dermatology 150:481–482. https://doi.org/10.1001/jamadermatol.2013.8759
Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, López-Vélez R, García-Hernández R et al (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoSNegl Trop Dis 11:e0006052. https://doi.org/10.1371/journal.pntd.0006052
Mathers CD, Ezzati M, Lopez AD (2007) Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoSNegl Trop Dis 1:e114. https://doi.org/10.1371/journal.pntd.0000114
World Health Organization. Leishmaniasisn.d.https://www.who.int/leishmaniasi/en/.
García Bustos MF, Barrio A, Prieto GG, de Raspi EM, Cimino RO, Cardozo RM et al (2014) In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis. J Parasitol 100:840–847. https://doi.org/10.1645/13-376.1
Coelho AC, Trinconi CT, Costa CHN, Uliana SRB (2014) In vitro and in vivo miltefosine susceptibility of a Leishmaniaamazonensis isolate from a patient with diffuse cutaneous leishmaniasis. PLoSNegl Trop Dis 8:e2999. https://doi.org/10.1371/journal.pntd.0002999
Özbilgin A, Çulha G, Uzun S, Harman M, Topal SG, Okudan F et al (2016) Leishmaniasis in Turkey: first clinical isolation of Leishmania major from 18 autochthonous cases of cutaneous leishmaniasis in four geographical regions. Trop Med Int Heal. https://doi.org/10.1111/tmi.12698
Toz SO, Culha G, Zeyrek FY, Ertabaklar H, Alkan MZ, Vardarlı AT et al (2013) A real-time ITS1-PCR based method in the diagnosis and species identification of leishmania parasite from human and dog clinical samples in Turkey. PLoSNegl Trop Dis 7:e2205. https://doi.org/10.1371/journal.pntd.0002205
Wakelin D (1989) Nature and nurture: overcoming constraints on immunity. Parasitology 99(Suppl):S21–35
Morrone A, Pitidis A, Pajno MC, Dassoni F, Latini O, Barnabas GA et al (2011) Epidemiological and geographical aspects of leishmaniasis in Tigray, northern Ethiopia: a retrospective analysis of medical records, 2005–2008. Trans R Soc Trop Med Hyg 105:273–280. https://doi.org/10.1016/j.trstmh.2011.02.003
Coelho AC, Trinconi CT, Costa CHN, Uliana SRB (2014) In vitro and in vivo miltefosine susceptibility of a leishmaniaamazonensis isolate from a patient with diffuse cutaneous leishmaniasis. PLoSNegl Trop Dis 8:1–11. https://doi.org/10.1371/journal.pntd.0002999
Soto J, Arana BA, Tolado J, Rizzo N, Vega JC, Diaz A et al (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38:1266–1272. https://doi.org/10.1086/383321
Monge-Maillo B, López-Vélez R, Saravolatz LD (2015) Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis 60:1398–1404. https://doi.org/10.1093/cid/civ004
Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L et al (2008) Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78:210–211
Dorlo TPC, van Thiel PPAM, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH et al (2011) Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoSNegl Trop Dis 5:e1436. https://doi.org/10.1371/journal.pntd.0001436
Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A et al (2007) Comparison of miltefosine and meglumineantimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103:33–40. https://doi.org/10.1016/j.actatropica.2007.05.005
Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81:151–157
RezaeiRiabi T, Sharifi I, MiraminMohammadi A, Khamesipour A, Hakimi PM (2013) Evaluation of a possible synergistic effect of meglumineantimoniate with paromomycin, miltefosine or allopurinol on in vitro susceptibility of leishmaniatropica resistant isolate. Iran J Parasitol 8:396–401
Özbilgin A, Çavuş İ, Kaya T, Yıldırım A, Harman M (2020) Comparison of in vitro resistance of wild leishmania isolates, which are resistant to pentavalent antimonial compounds, against drugs used in the treatment of leishmaniasis. TurkiyeParazitolojiiDerg 44:12–16. https://doi.org/10.4274/tpd.galenos.2019.6661
Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E (2008) Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 19:394–396
Killingley B, Lamb LEM, Davidson RN (2009) Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol 103:171–175. https://doi.org/10.1179/136485909X398177
Prevention C-C for DC and CDC—Leishmaniasis—Resources for health Professionals 2017
Tuntland T, Ethell B, Kosaka T, Blasco F, Zang R, Jain M et al (2014) Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at novartis institute of biomedical research. Front Pharmacol. https://doi.org/10.3389/fphar.2014.00174
Acknowledgements
The authors would like to thank Ege University Research Funds for funding this research, and ‘Parasite Bank’ in Celal Bayar University Faculty of Medicine for keeping and supplying the isolates.
Funding
This project was supported by Research Funds of Ege University with the Project no: 17-TIP-017.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
This study was approved by the Celal Bayar University Local Ethical Committee for Laboratory Animals (No: 77.637.435‐55‐27.09.2016).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tunalı, V., Harman, M., Çavuş, İ. et al. Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis. Acta Parasit. 66, 354–360 (2021). https://doi.org/10.1007/s11686-020-00285-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11686-020-00285-0